Article
Ovarian cancer mutational processes drive site-specific immune evasion.
Nature - 1 Dec 2022
Vázquez-García Ignacio, Uhlitz Florian, Ceglia Nicholas, Lim Jamie L P, Wu Michelle, Mohibullah Neeman, Niyazov Juliana, Ruiz Arvin Eric B, Boehm Kevin M, Bojilova Viktoria, Fong Christopher J, Funnell Tyler, Grewal Diljot, Havasov Eliyahu, Leung Samantha, Pasha Arfath, Patel Druv M, Pourmaleki Maryam, Rusk Nicole, Shi Hongyu, Vanguri Rami, Williams Marc J, Zhang Allen W, Broach Vance, Chi Dennis S, Da Cruz Paula Arnaud, Gardner Ginger J, Kim Sarah H, Lennon Matthew, Long Roche Kara, Sonoda Yukio, Zivanovic Oliver, Kundra Ritika, Viale Agnes, Derakhshan Fatemeh N, Geneslaw Luke, Issa Bhaloo Shirin, Maroldi Ana, Nunez Rahelly, Pareja Fresia, Stylianou Anthe, Vahdatinia Mahsa, Bykov Yonina, Grisham Rachel N, Liu Ying L, Lakhman Yulia, Nikolovski Ines, Kelly Daniel, Gao Jianjiong, Schietinger Andrea, Hollmann Travis J, Bakhoum Samuel F, Soslow Robert A, Ellenson Lora H, Abu-Rustum Nadeem R, Aghajanian Carol, Friedman Claire F, McPherson Andrew, Weigelt Britta, Zamarin Dmitriy, Shah Sohrab P
Abstract excerpt
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability1-4 patterned by distinct mutational processes5,6, tumour heterogeneity7-9 and intraperitoneal spread7,8,10. Immunotherapies have had limited efficacy in HGSOC11-13, highlighting an unmet need to assess how mutational processes and the anatomical sites of tumour foci determine the immunological states of the tumour...
Read the complete abstract on PubMed